AGENUS INC Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
AGENUS INC (AGEN) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $200.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2026-08-07
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $200.00K.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $200.00K.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $100.00K.
- 2025-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $200.00K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $200.00K 10-Q · filed 2026-08-07 |
| 2026-03-31 | $200.00K 10-Q · filed 2026-05-11 |
| 2025-09-30 | $100.00K 10-Q · filed 2025-11-10 |
| 2025-06-30 | $200.00K 10-Q · filed 2025-08-11 |
| 2025-03-31 | $300.00K 10-Q · filed 2025-05-12 |
| 2024-09-30 | $100.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $300.00K 10-Q · filed 2024-08-08 |
| 2024-03-31 | $400.00K 10-Q · filed 2024-05-07 |
| 2023-09-30 | $100.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $600.00K 10-Q · filed 2023-08-08 |
| 2023-03-31 | $1.10M 10-Q · filed 2023-05-09 |
| 2022-09-30 | $600.00K 10-Q · filed 2022-11-08 |
| 2022-06-30 | $1.20M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $1.60M 10-Q · filed 2022-05-10 |
| 2021-09-30 | $600.00K 10-Q · filed 2021-11-09 |
| 2021-06-30 | $1.10M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $1.60M 10-Q · filed 2021-05-07 |
| 2020-09-30 | $600.00K 10-Q · filed 2020-11-09 |
| 2020-06-30 | $1.10M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $1.40M 10-Q · filed 2020-05-11 |
| 2019-09-30 | $500.00K 10-Q · filed 2019-11-07 |
| 2019-06-30 | $1.00M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $1.40M 10-Q · filed 2019-05-10 |
| 2018-09-30 | $500.00K 10-Q · filed 2018-11-07 |
| 2018-06-30 | $1.00M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $1.50M 10-Q · filed 2018-05-10 |
| 2017-09-30 | $900.00K 10-Q · filed 2017-11-07 |
| 2017-06-30 | $1.10M 10-Q · filed 2017-08-07 |
| 2017-03-31 | $1.60M 10-Q · filed 2017-05-04 |
| 2016-09-30 | $800.00K 10-Q · filed 2016-11-09 |
| 2016-06-30 | $1.30M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $1.80M 10-Q · filed 2016-05-09 |
| 2015-09-30 | $134.00K 10-Q · filed 2015-11-04 |
| 2015-06-30 | $281.00K 10-Q · filed 2015-08-03 |
| 2015-03-31 | $407.00K 10-Q · filed 2015-05-01 |
| 2014-09-30 | $137.00K 10-Q · filed 2014-10-31 |
| 2014-06-30 | $293.00K 10-Q · filed 2014-08-01 |
| 2014-03-31 | $442.00K 10-Q · filed 2014-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |